Pfizer stops enrollment in Paxlovid trial in standard-risk population

Published by
Reuters

(Reuters) – Pfizer Inc said on Tuesday it would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group. The drug has emergency use authorization for high-risk groups in which it has been effective in reducing hospitalizations and deaths. The new data, however, showed a 51% relative risk reduction in standard-risk groups, which the company said was not statistically significant. The standard-risk population usually includes people who do not have health conditions t…

Read More

Leave a Reply